Crux Biomedical

Our main objective is to create dependable devices that protect people from pulmonary embolisms and hypertension. The corporation was established in 2004 and since then, we continuously advance our technologies and methods of work to provide people with the most efficient and safe devices. Thus, we have created vena cava filters to prevent this dan... gerous disease. Pulmonary embolism is a severe disease that blocks one of the arteries of the lungs. Commonly, it's caused by blood clots. As they block the arteries, they threaten human life and so, this disease is taken seriously by our professional staff. We use a revolutionary device called a vena cava filter. Its main objective is to prevent the development of this life-threatening disease by trapping blood clots. Pulmonary hypertension is a much rarer disease, which affects circa 150 thousand people in North Amercia and Europe. It is also one of the most frequently misdiagnosed diseases. Pulmonary hypertension is a far more dangerous condition that the usual systemic hypertension and can easily be fatal - in fact, only twenty years ago it was considered a death sentence. Our corporation creates, manufactures, and advances various vascular devices, which can be implanted. After the successful implantation, patients are not endangered by pulmonary embolism anymore. Crux Biomedical helps patients in every corner of the United States of America. This severe disease is widely spread in the USA. Approximately 600,000 patients suffer from it and about 120,000 - 150,000 because of it. The development of the disease may be caused by other substances, but it's a rarity. Our experts know that blood clots are the main source of its development. Therefore, all our knowledge, experience, and skills are targeted at the creation and improvement of special filters that successfully trap blood clots and thus, prevent the disease. You can fully trust our creations. Our corporation and its devices are officially approved by the FDA. We have been awarded four important patents ...Read More